This study is taking place at UCSF (in San Francisco).
If you participate, you will be randomly assigned to one of two
groups. Both groups will receive LDN for eight weeks and a placebo for
eight weeks. One of the groups will receive the LDN first, and the
other group will receive it last. Neither you nor your doctor will know
which group you are in until after the study is complete.
If you enroll in this study, you must continue to take any MS
medications that you’re already taking. For eight weeks, you will take
either the LDN or the inactive placebo every night before going to bed
between the hours of 9:00 PM to 3:00 AM. You will take neither drug for
the ninth week. Finally, you will take the other drug for the last
eight weeks of the trial. You will be asked to answer a questionnaire
(called “MSQLI54”) at the baseline and at weeks 8 and 17.
To request additional information, phone (415) 514-3815.